Seaman, Andrew http://orcid.org/0000-0002-8955-6210
Leichtling, Gillian
Stack, Erin
Gray, Mary
Pope, Justine
Larsen, Jessica E.
Leahy, Judith M.
Gelberg, Lillian
Korthuis, P. Todd
Funding for this research was provided by:
National Institute on Drug Abuse (UH3DA044831)
Article History
Accepted: 15 December 2020
First Online: 20 January 2021
Compliance with Ethical Standards
:
: Andrew Seaman has received investigator-initiated research funding from Gilead Sciences and Merck & Co Pharmaceuticals unrelated to the content of this research. All other authors report no financial conflicts of interest. Dr. Korthuis serves as principal investigator for NIH-funded studies that accept donated study medications from Alkermes (extended-release naltrexone) and Indivior (buprenorphine).
: The questionnaire, methodology, and study protocol for this study were approved by the Institutional Review Board of Oregon Health and Sciences University (IRB#:STUDY00020911).
: Verbal informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent for publication of quotes and summarized interview responses in the academic literature.
Free to read: This content has been made available to all.